{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-25-000094","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.660670+00:00","generated_at":"2026-05-17T21:29:41.330417+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Praxis reports RADIANT study positive: 56.3% median seizure reduction; Q2 net loss $71.1M","bullets":["Vormatrigine in focal onset seizures (n=37): 56.3% median reduction in seizure frequency over 8 weeks; 22% achieved 100% reduction in last 28 days.","Cash and investments $446.6M at June 30, 2025, providing runway into 2028.","Q2 2025 net loss $71.1M vs $32.7M in Q2 2024; R&D expenses rose to $63.0M from $27.3M.","Relutrigine received FDA Breakthrough Therapy Designation for SCN2A and SCN8A DEEs in July 2025.","Initiated registrational studies: EMERALD (broad DEEs with relutrigine) and EMBRAVE3 (SCN2A GoF with elsunersen)."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-25-000094","json":"https://secwatch.observer/filing/0001689548-25-000094.json","markdown":"https://secwatch.observer/filing/0001689548-25-000094.md","text":"https://secwatch.observer/filing/0001689548-25-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000094/0001689548-25-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000094/prax-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:29:41.330417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}